• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Australia's TGA approves suspension for subfoveal CNV from wet AMD


Australia's Therapeutic Goods Administration (TGA) approved Alcon's 15-mg anecortave acetate suspension (Retaane) for the treatment of subfoveal choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). The drug should be used where there is a classic component.

As part of a clinical trial agreement, the company will provide the suspension to the U.S. National Eye Institute for a study of wet AMD.

The multicenter, randomized, prospective clinical trial will investigate the long-term safety and efficacy of 15-mg anecortave acetate suspension in patients with all forms of wet AMD and who are undergoing intravitreal bevacizumab (Avastin, Genentech) therapy.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.